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Abstract
Background: Psychotropic paediatric prescribing trends are increasing internationally. The aim of this study is to examine
the prevalence and secular trends in psychotropic prescribing in Irish children and adolescents between 2002 and 2011.
Methods: Data was obtained from the Irish General Medical Services (GMS) scheme pharmacy claims database
from the Health Service Executive Primary Care Reimbursement Services (HSE-PCRS). Prescribing rates per 1000
eligible population and associated 95 % confidence intervals (CIs) were calculated across years (2002–2011), age
groups (0–4, 5–11, 12–15 years) and gender. Rates of concomitant prescriptions for psycholeptics and
antidepressants were also examined. The total expenditure costs were calculated and expressed as a percentage of
the cost of all prescriptions for this age group (≤15 years).
Results: In 2002, 3.77/1000 GMS population (95 % CI: 3.53–4.01) received at least one psychostimulant prescription and this
rate increased to 8.63/1000 GMS population (95 % CI: 8.34–8.92) in 2011. Methylphenidate was the most frequently prescribed
psychostimulant. For both males and females the prevalence of medication use was highest among the 12–15 year old
group. On average, a psycholeptic medication was prescribed to 8 % of all psychostimulant users and an antidepressant was
concomitantly prescribed on average to 2 %. Total expenditure rose from €89,254 in 2002 to €1,532,016 in 2011.
Conclusions: The rate and cost of psychostimulant prescribing among GMS children and adolescents in Ireland increased
significantly between 2002 and 2011. Further research is necessary to assess the safety, efficacy and economic impact of
concomitant psychotropic prescribing in this population.
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Background
Psychotropic paediatric prescribing is increasing in the
USA, Europe and Australia [1, 2]. One of the main indi-
cations for psychotropic prescribing in children is the
psychostimulant treatment of attention deficit hyper-
activity disorder (ADHD) [3]. This disorder is defined by
a combination of developmentally inappropriate and
maladaptive levels of inattention, hyperactivity and im-
pulsivity which persist for at least 6 months and are
present in more than one social environment [4]. Epide-
miologic studies using standardised diagnostic criteria
suggest that 3 to 8 % of the school-aged population
(elementary through high school) may suffer from
ADHD [5, 6]. A recent systematic review examined
ADHD prevalence estimates internationally by aggregat-
ing 154 prevalence studies of ADHD conducted from
1985 to 2012 [7]. The findings demonstrate that there is
no evidence to suggest an increase in the number of
children in the community who fulfil the criteria for
ADHD when standardised diagnostic procedures are ad-
hered to [7]. However, prescribing trends do not support
this finding, where the prescription of psychostimulants
has significantly increased in most countries worldwide
for both pre-school and school-aged children [8–12].
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Although ADHD is mainly treated with stimulants, a
multimodal comprehensive treatment approach with
individualised psychosocial interventions is recom-
mended [4, 13]. One study assessing paediatricians’ and
child psychiatrists’ professional approaches and attitudes
to attention difficulties in the UK indicated that more
than 60 % of both groups were prepared to prescribe
stimulant medication without a formal diagnosis which
is inconsistent with current prescribing guidelines [14].
Other studies have also highlighted wide regional vari-
ation in prescribing rates of psychostimulants [15, 16].
In terms of stimulant prescribing, methylphenidate and
dexamfetamine are widely used in Europe and North
America to reduce the symptoms of the condition [17].
Evidence from recent meta-analyses support their use
with favourable effects demonstrated on measures of
hyperactive, inattentive and impulsive behaviour [18,
19]. According to current European treatment guidelines
[13] and licensing authorities, methylphenidate is con-
sidered off-label for children under 6 years of age and
dexamfetamine use is not licensed for children under
3 years. Therefore caution is required in relation to their
prescription in pre-school children [20]. A further pre-
scribing challenge faced by clinicians treating children
with ADHD relates to the prescribing of multiple medi-
cines as these children are more likely to have a diagno-
sis of other neurobehavioral disorders and to receive
non-stimulant psychotropic medications [4]. The benefit
of a polypharmacy treatment strategy for children with
ADHD is unclear and there remain questions regarding
efficacy, safety and role of any combination therapy [21].
The aim of the current study is to determine the level
of psychotropic prescribing in an Irish paediatric popula-
tion (aged 0–15 years) receiving free medical care over a
10 year period (2002–2011), using dispensed medication
data. Specifically, overall stimulant prescribing rates,
types of stimulant drugs prescribed and overall cost of
stimulant prescribing in Irish children are examined.
Methods
Study design
This was a national cohort study of children aged 0–
15 years between January 2002 and December 2011. The
STROBE standardised reporting guidelines were followed
to ensure the standardised conduct and reporting of the
research [22]. The methodology and design of this study
are similar to a recently published study about antibiotic
prescribing trends in a paediatric sub-population in
Ireland [23].
Data source and study population
Data was obtained from the Irish General Medical Ser-
vices (GMS) scheme pharmacy claims database from the
Health Service Executive Primary Care Reimbursement
Services (HSE-PCRS) [24]. The GMS scheme is means
tested and provides free health services to those who are
unable to afford them. It represents approximately 28 %
of Irish children but over-represents socially deprived
populations [23]. The GMS database contains routinely
collected data from pharmacy claims for dispensed med-
ications. No information on diagnosis or disease condi-
tion is available.
The GMS database contains basic demographic infor-
mation (age and sex) and all prescription items are
coded using WHO’s Anatomical Therapeutic Chemical
(ATC) classification [25]. Data is collected by the HSE-
PCRS according to a number of pre-defined age groups.
For this study, data was extracted for those aged 0–
15 years (0–4, 5–11 and 12–15 years). The next age
band (16–24 years) included a large proportion of adults
and was therefore excluded from the current analysis.
All psychostimulant medications classified according to
the ATC system, were extracted for children aged ≤15
for the years 2002–2011. Relevant medication codes
were: N06BA02, N06BA04, N06BA07 and N06BA09
[25]. For the purposes of our study, we defined consecu-
tive users as children and adolescents who were pre-
scribed a psychostimulant medication for ≥3 consecutive
months during the study period. In the absence of infor-
mation on diagnosis, this cut point was chosen to take
into account children who may have been dispensed
such a medication for a shorter period of time.
Concomitant psychotropic medication prescriptions
were also extracted from the GMS database. All psycho-
leptic medications (ATC category N05, which includes
antipsychotics (N05A), anxiolytics (N05B) and hypnotics
and sedatives (N05C)) and additionally psychoanaleptic
medications (i.e. antidepressants, ATC category N06A)
were extracted.
Data was also obtained for the net ingredient cost
(NIC) of each drug prescribed, which refers to the actual
cost of the psychostimulant drugs. In addition, total ex-
penditure was also calculated, which refers to the final
cost to the Irish government to provide the medication
for free and incorporates costs such as pharmacy fees
and VAT in addition to the NIC.
Ethical approval
Permission was given by the data controller to use the
GMS dataset if anonymised and analysed at group level.
Therefore, it was unnecessary to seek specific ethical ap-
proval for this study.
Data analysis
Prescribing rates for all medications were compared
across years, age groups (0–4, 5–11 and 12–15 years)
and gender. The prescribing trends are described in
terms of annual prescription rates of psychostimulants
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and are interpreted as the prevalence of children receiv-
ing at least one psychostimulant prescription per 1000
GMS population, as determined from the GMS database
Prescribing rates per 1000 eligible population and associ-
ated 95 % confidence intervals (CIs) were calculated
across years, age groups and gender. Additionally, an-
nual NIC and the total expenditure costs were calculated
and expressed as a percentage of the cost of all prescrip-
tions for this age group (≤15 years).
A negative binomial regression model was used to de-
termine trends in prescribing rates. The log of the GMS
population was used as the offset term and year, age
group, gender and all possible interactions between these
variables were included in the model. The Bonferroni
method was used to control the overall Type I error rate
in making multiple comparisons of means. P-values
<0.05 were deemed significant. Data analyses was per-
formed using Stata version 11 (StataCorp, College Sta-
tion, Tx, USA) and SAS version 9.3 (SAS Institute Inc.
Cary, NC, USA).
Results
Population sample
During the study period (January 2002 to December
2011), the number of children ≤15 years in Ireland iden-
tified from the HSE-PCRS pharmacy database ranged
between 188,833 and 311,579. On average, 51 % of the
study population were male and 49 % were female.
Prescribing trends
Table 1 displays the prevalence rate of psychostimulant
prescribing (per 1000 GMS population) over the study
period. In 2002, 3.77/1000 GMS population (95 % CI:
3.53–4.01) received at least one psychostimulant pre-
scription and this rate increased to 8.63/1000 GMS
population (95 % CI: 8.34–8.92) in 2011, representing a
two-fold increase in psychostimulant prescribing over
the study period. The prevalence increased each year
except for 2006 where there was a non-significant
decrease.
During the study period methylphenidate was the
most frequently prescribed psychostimulant. The preva-
lence increased from 3.68/1000 GMS population (95 %
CI: 3.44–3.92) in 2002 to 7.51/1000 GMS population
(95 % CI: 7.24–7.78) in 2011. Rates of dexamfetamine
remained relatively stable over the 10 years, fluctuating
between 0.08/1000 GMS population (95 % CI: 0.05–
0.11) and 0.15/1000 GMS population (95 % CI: 0.10–
0.20). Atomoxetine became available for prescribing in
Ireland in January 2007 and immediately became the
second most commonly prescribed drug (1.00/1000
population, 95 % CI: 0.88–1.12). Since 2007 rates of ato-
moxetine have steadily increased to 1.57/1000 popula-
tion (95 % CI: 1.45–1.70) in 2011. Figure 1 illustrates the
prescribing rates of these drugs per 1000 GMS popula-
tion over the study period. Modafinil was rarely pre-
scribed between 2002 and 2011 with prevalences of less
than 0.02/1000 GMS population.
Gender and age
Figure 2 displays the rates of prescribing classified by
gender and age group during the study period. Statisti-
cally significant differences were found for both gender
and age. In the 5–11 and 12–15 year age categories,
male children were significantly more likely to receive a
psychostimulant prescription than females across all
years. The only significant difference between males and
females for the 0–4 year old groups was for 2004. For
males, from 2006 onwards, the 12–15 year old group
was significantly more likely to receive a psychostimu-
lant prescription than the 5–11 year old group. For fe-
males, there was no significant difference in prevalence
between the 12–15 year old group and the 5–11 year old
group until 2009. Since 2009, 12–15 year old females
Table 1 Prescribing rates (95 % confidence intervals) and the cost of prescribing (% of all prescribing) psychostimulants to children
aged 0–15 years from 2002 to 2011
Year Rate of prescribing per 1000 GMS population
(95 % confidence interval)
Net ingredient cost in
€ (% of all prescriptions)
Total expenditure in
€ (% of all prescriptions)
2002 3.77 (3.53–4.01) 68,945(0.70) 89,254 (0.64)
2003 4.91 (4.64–5.18) 236,180 (2.07) 268,810(1.67)
2004 5.67 (5.37–5.97) 351,204 (2.81) 393,406 (2.28)
2005 6.84 (6.51–7.17) 464,287 (3.34) 518,225 (2.75)
2006 6.77 (6.46–7.08) 529,926 (3.36) 596,176 (2.76)
2007 7.42 (7.10–7.74) 783,868 (4.42) 863,930 (3.59)
2008 7.61 (7.30–7.92) 940,133 (4.85) 1,036,285 (3.89)
2009 7.73 (7.43–8.03) 1,100,869 (5.10) 1,205,242 (4.00)
2010 7.80 (7.52–8.08) 1,279,381(5.33) 1,387,443 (4.12)
2011 8.63 (8.34–8.92) 1,410,443 (5.22) 1,532,016 (4.01)
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were more likely to receive a psychostimulant prescrip-
tion than 5–11 year old females.
In all, 61 % of children were prescribed at least one
psychostimulant medication for ≥3 consecutive months.
The percentage was significantly higher in boys than in
girls (63 % versus 54 %), and differed across age groups;
it was 30 % in the 0–4 year olds, 63 % in the 5–10 year
old group and 60 % in the 12–15 year old group.
Concomitant medications
Table 2 displays the percentage of psychostimulant users
taking a concomitant medication during the study
period. On average, a psycholeptic medication was pre-
scribed to 8 % of all psychostimulant users and an anti-
depressant was concomitantly prescribed on average to
2 %. The proportion of a psychotropic (psycholeptic or
antidepressant) concomitant medication did not change
significantly during the observation period between 2002
and 2011.
Cost
The net ingredient cost of psychostimulants increased
from €68,945 in 2002 to €1,410,433 in 2011. Total ex-
penditure (approximate cost to the State) rose from
€89,254 in 2002 to €1,532,016 in 2011. This equates to
an average yearly increase of approximately €160,000.
Table 1 displays the cost of psychostimulant prescribing
between 2002 and 2011.
Discussion
Statement of principal findings
This study found that the rate of psychostimulant pre-
scribing among children and adolescents in Ireland in-
creased from 2002 to 2011, with the exception of 2006
where a small decrease was noted. For both males and
Fig. 1 Prescribing rates of the three most frequently prescribed psychostimulants per 1000 GMS population aged 0–15 years old for 2002–2011
Fig. 2 Prescribing rates of psychostimulants per 1000 GMS population aged 0–15 years old for 2002–2011 classified by gender and age group
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females the prevalence of medication use was highest
among the 12–15 year old group and declined with
younger age. The cost of prescribing also rose signifi-
cantly with the total expenditure in 2011 over 17 times
higher than in 2002. The use of concomitant medication
remained stable during the study period.
Results in the context of the current literature
Our results indicate that the prescribing prevalence of
psychostimulants in Ireland is lower when compared to
other countries. The highest observed rates during
2002–2011 are comparable with German data in 2000
[8], whereas prescribing in Netherlands is at least 1.5–2
times higher than in Ireland, and prescribing in USA at
least 5 to 10 times higher [8]. In contrast, our findings
are broadly similar to a recent population based study in
the UK where the overall prevalence of psychostimulant
prescribing increased over the 6 year study period
(2002–2008) from 4.83 to 9.18 per 1000 children aged
6–12 years [26]. Methylphenidate was the most fre-
quently prescribed psychostimulant in Ireland, which is
consistent with findings from other studies [8, 17, 27,
28]. We found that boys aged between five and 15 years
were more likely to be prescribed a psychostimulant
medication than girls. Male to female treatment ratios
from the literature are similar, ranging from about 3.4:1
to 5.8:1 [9, 28, 29]. In addition to a higher prevalence
rate of ADHD in boys [30], the gender difference may
also indicate a higher diagnosis and referral rate for boys
which may be influenced by more disruptive or aggres-
sive behaviour patterns in boys when compared to girls.
Our results also demonstrate that from 2006 onwards,
boys aged 12–15 years were significantly more likely to
receive a psychostimulant prescription than the 5–
11 year old group. However, the majority of boys in both
age groups were prescribed at least one psychostimulant
for three or more consecutive months. These findings
are in contrast to those reported in the UK [26] and in
the Netherlands [31] where the highest prevalence of
psychostimulant prescribing was observed in younger
boys. These differences in prescribing trends may reflect
the differing healthcare access and referral pathways and
prescribing practices in these countries.
Prescribing trends among girls aged 5–15 years
remained stable between 2002 and 2009 in our study.
This is in contrast to a UK study that found that the
relative increase in prescribing patterns during the study
period was lower in boys when compared to girls the
same age-the increase in prevalence in girls aged 6–
12 years was 2.1 fold compared to an increase of 1.9 fold
for their male counterparts [26]. Similar trends were
observed in Dutch study where the prevalence and inci-
dence rates of psychostimulant prescribing were consist-
ently higher among boys than girls from 2000 to 2007,
however the largest increases were observed in girls over
the study period [31].
Prescribing rates among pre-school children (0–
4 years) were low in our study and did not significantly
increase during the study period. This is in keeping with
international literature where there are low levels of psy-
chostimulant treatment in children under 6 years re-
ported [27, 29]. Almost one third of children in this age
category received a prescription for ≥3 months and me-
thylphenidate was also the most commonly prescribed
drug. These prescriptions are considered off-label as
European guidelines [13] do not permit the prescription
of methylphenidate for children under 6 years of age. In
addition, safety and efficacy data for psychostimulant use
in this age group is not available. However, our lack of
information of indication for prescription limits the
wider comparability of the results. Co-prescribing was
most common with a psycholeptic medication (8 %) and
less so, with anti-depressants (2 %). This differs slightly
with the literature, which found stimulants were most
Table 2 Percentage of psychostimulant users (aged 0–15 years) from 2002 to 2011 taking concomitant medications
Year Psycho-stimulant
users (n)
Concomitant
Psycholeptics (%)
Concomitant
Anti-depressants (%)
Psycholeptics +
Antidepressants (%)
2002 936 6.94 2.67 0.96
2003 1223 9.24 2.94 1.06
2004 1376 6.61 2.62 0.94
2005 1650 8.67 1.76 0.91
2006 1779 8.32 1.52 0.67
2007 2066 8.03 1.50 0.44
2008 2280 8.46 2.28 1.05
2009 2591 8.53 2.24 0.96
2010 2888 8.03 1.77 0.66
2011 3349 7.73 1.97 0.78
Legend Table 2: Percentage of psychostimulant users aged 0–15 years who also received concomitant psycholeptic (column 3) or antidepressant (column 4)
medication from 2002 to 2011. Psycholeptic medication includes antipsychotics, anxiolytics and hypnotics and sedatives
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commonly prescribed with anti-depressants [8, 28, 32]
and alpha-agonists [8, 28]. Potential drug interactions
between psycholeptics, particularly when used as anti-
convulsants, and stimulants have been highlighted [20].
Few studies have evaluated the long-term safety of drugs
for ADHD. A recent systematic review summarised the
findings of eight clinical trials that examined the safety
of medicines used for ADHD in children [33]. There was
heterogeneity between the studies relating to data report-
ing and duration of follow-up (ranging from 1 to 4 years).
However, the rate of treatment related adverse events
(AE) ranged from 58 to 78 % in the included studies. The
most common AEs included insomnia, headache, de-
creased appetite and abdominal pain. Furthermore, the
rate of discontinuation ranged from 8 to 25 % due to AEs
[33], highlighting the need for systematic monitoring of
long-term safety of prescribing.
An increasing cost to the state due to psychostimulant
prescribing was noted in our study, with expenditure in
2011 at approximately €1.5 million representing an aver-
age annual increase of approximately €160,000. The ris-
ing costs can most likely be attributed to the prescribing
trend and rising drug costs. It is worth noting the in-
creased cost of the long acting formulations compared
to the immediate release formulations [13], the former
being associated with improved compliance enhancing
treatment in certain patient groups.
Changes in licensing and regulation should be consid-
ered when interpreting this data. The timescale of the
study coincides with the revocation of the Irish Medical
Preparations (Control of Amphetamines) Regulations
and the licensing of more expensive controlled release
preparations of methylphenidate and atomoxetine.
Strengths and weaknesses of the study
This study examined prescribing trends in Irish children,
aged 0–15 years, over a 10 year period from 2002 to
2011 using data from a national prescribing database.
However, the findings from our study need to be
interpreted in the context of the study limitations. A
significant drawback of the study is that our database
only contains routinely collected data for pharmacy
dispensed medications with no information on diag-
nosis or indication for prescription. In the absence of
this information, we examined duration of prescrip-
tion to take into account children who may have been
dispensed a psychostimulant medication for a shorter
period of time. Secondly, we have not examined the
dosage form or quantity of medication dispenses per
prescription. Therefore the results of this paper may
not accurately reflect prescribing patterns among pa-
tients with a clinical diagnosis of ADHD. Thirdly, our
prescribing figures cannot be used as an estimate for the
entire Irish paediatric population as study participants
were means tested which results in an over-representation
of lower socioeconomic groups [34, 35]. This may result
in an over-inflation of the true prescription rates for Irish
children; given that children from more socially deprived
backgrounds are more likely to receive a psychostimulant
prescription than their better off counter-parts [16].
Analysis of prescribing data among children and ado-
lescents with private healthcare insurance in Ireland
would facilitate more robust conclusions regarding
the role of socioeconomic status on prescribing pat-
terns of psychostimulants in the Irish context. Cau-
tion is also required when comparing findings with
results from other countries, as in addition to meth-
odological differences of studies, different licensing
and reimbursement policies for medication may exist.
Furthermore, no data was available on the clinical in-
dication for treatment and professional details (spe-
cialist versus generalist) of the doctor initiating the
prescription.
Clinical implications and areas for further research
The management of children and adolescents with
ADHD is a complex process. To this end, clinicians
should evaluate the need for prescribing in this popula-
tion on a case-by-case basis, taking into account the se-
verity of the symptoms and the risk-benefit profile for
different treatment alternatives, as per the current guide-
lines [36]. However, the longer-term safety of many
medications used concomitantly with stimulants is
largely unknown. Therefore, further research is neces-
sary to assess the risk-benefit profile of concomitant psy-
chotropic medication use in children with ADHD [36].
Geographical variation in psychostimulant prescribing
has been also been reported in other studies and
warrants further research [15, 16]. Furthermore, psy-
chostimulant prescribing in additional age categories,
particularly the 16–24 year old group, should be ex-
plored to gain an insight into prescribing patterns in
early adulthood. Finally, previous studies have also re-
ported that psychiatrists are more likely to prescribe
psychotropic medications in this population than pri-
mary care physicians, highlighting the need for further
investigation into variation in prescribing practices.
Conclusion
The rate of psychostimulant prescribing among GMS
children and adolescents in Ireland increased between
2002 and 2011. The use of concomitant medication
remained stable during the study period. Though in-
creasing, Irish prescribing of psychostimulants is modest
when compared to the US and other European countries.
Further research is necessary to assess the long-term
efficacy, safety, and economic impact of concomitant psy-
chotropic prescribing in this population.
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